Aurobindo Pharma consolidated Q4 net profit up 79%
IndiaTimes
Aurobindo Pharma's strong financial performance in Q4FY24 and FY24, driven by revenue growth and net profit increase, was supported..
Aurobindo Pharma's strong financial performance in Q4FY24 and FY24, driven by revenue growth and net profit increase, was supported..
The CBI disclosed that K Kavitha allegedly pressured Aurobindo Pharma promoter to pay Rs 25 crore to AAP for Delhi's excise zones,..
The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023 and the Worldwide Pregabalin Market Size is Expected to..